Skip to main content

Table 2 Annual transition probabilities in the economic model

From: Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

From To Mean SE Source Probabilistic Sensitivity Analysis
Distribution Lower Upper
F0-F2 F3 0.025 0.004 [21, 32] Beta 0.018 0.033
F3 F4 0.037 0.007 [21, 32] Beta 0.025 0.052
F4 DCC 0.039 0.010 [21, 33] Beta 0.022 0.061
HCC 0.014 0.010 [21, 33] Beta 0.002 0.039
SVR F4 DCC 0.000 0.000 expert opinion Beta 0.000 0.000
HCC 0.005 0.001 [34] Beta 0.004 0.007
DCC HCC 0.014 0.010 [21, 33] Beta 0.002 0.039
LT 0.020 0.003 [21, 35] Beta 0.015 0.026
LrD 0.130 0.010 [21, 33] Beta 0.111 0.150
HCC LT 0.020 0.003 [32, 35] Beta 0.015 0.026
LrD 0.430 0.030 [21, 33] Beta 0.372 0.489
LT LrD 0.150 0.023 [21, 36] Beta 0.109 0.197
pLT LrD 0.057 0.009 [21, 36] Beta 0.041 0.075
All-cause mortality Age/gender specific   Life Tables, German Federal Office of Statistics    
  1. DCC decompensated cirrhosis, HCC hepatocellular carcinoma, SVR sustained virologic response, LT liver transplant, LrD Liver related death, pLT post liver transplant, fibrosis states F0-F4 according to METAVIR